Search clinical trials for: docetaxel, epirubicin and cyclophosphamide plus endostar

Total 543 results

Hebei Medical University Fourth Hospital

Unknown

A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer (TENDENCY)

Stage III Breast Cancer

China
Jules Bordet Institute
Sanofi

Terminated

Early Cardiac Toxicity of Adjuvant CT in Elderly BC.

Breast Cancer

Belgium
German Breast Group
AGO Study Group

Completed

Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer (GeparQuinto)

Breast Cancer

Germany
Zhejiang Provincial People's Hospital

Not yet recruiting

Evaluating Xihuang Pill to Improve the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer

Breast Cancer | Chemotherapy Effect
Simcere Pharmaceutical Co., Ltd

Unknown

Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC)

Advanced NSCLC | Recurrent NSCLC

China
Fudan University
Chinese Anti-Cancer Association

Completed

Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy

Primary Breast Cancer

China
Guangdong Provincial People's Hospital

Completed

TCH Versus EC-TH as Neoadjuvant Treatment for HER2-Positive Breast Cancer (neoCARH)

HER2-Positive Breast Cancer

China
Xijing Hospital

Unknown

Trial of Neoadjuvant Endostar, Docetaxel and Epirubicin for Patients With Breast Cancer (CBCRT01)

Breast Cancer

China
Danish Breast Cancer Cooperative Group
Sanofi; Fonden Til Fremme af Klinisk- Eksperimentel Cancerforskning; Dako

Completed

Epirubicin or Not in Patients With TOP2A (Topoisomerase (DNA) II Alpha (170kD)) Normal Early Breast Cancer (READ)

Breast Neoplasms

Denmark
Xijing Hospital

Completed

Neoadjuvant Endostatin and Chemotherapy for Breast Cancer

Breast Cancer

China
Guangdong Provincial People's Hospital
First Affiliated Hospital, Sun Yat-Sen University; Henan Cancer Hospital; Dongguan... and other collaborators

Completed

DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer

Triple-Negative Breast Cancer

China
Shanghai Jiao Tong University School of Medicine

Terminated

Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer (NATT)

Breast Cancer

China
Sheffield Teaching Hospitals NHS Foundation Trust

Completed

Investigating the Biological Effects of the Addition of Zoledronic Acid to Pre-operative Chemotherapy in Breast Cancer (ANZAC)

Breast Cancer

United Kingdom
Centre Jean Perrin

Completed

Assessment of the Efficacy of the Neoadjuvant Combination: "Chemotherapy-Targeted Therapy" in Breast Cancer. (TVA)

Pathological Response Rate

France
Simcere Pharmaceutical Co., Ltd

Unknown

Safety Study of Combined Chemotherapy and Endostar to Untreated Patients With Advanced Melanoma (melanoma)

Advanced Melanoma | Untreated Patients

China
Xijing Hospital
Yantai Medgenn Ltd.

Unknown

Impact of Endostar Combined With Chemotherapy on the Angiogenesis of Advanced Non-small Cell Lung Cancer (NSCLC)

Lung Neoplasms

China
Fudan University

Unknown

Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer

Breast Neoplasms | Chemotherapy | Adjuvant

China
Lagos State University

Unknown

The Safety and Efficacy of Jobelyn in the Treatment of Breast Cancer Patients

Haematological Abnormality

Nigeria
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial

Breast Cancer | Neoadjuvant Therapy | Hormone Receptor-positive Breast Cancer | HER2-low-expressing Breast Cancer

China
European Organisation for Research and Treatment...
Pfizer; ETOP IBCSG Partners Foundation; UNICANCER; Breast International Group; SOLTI... and other collaborators

Active, not recruiting

Adjuvant Palbociclib in Elderly Patients With Breast Cancer (Appalaches)

Breast Cancer Stage II | Breast Cancer Stage III

Spain, France, Italy, Belgium, Jordan, Poland, Germany, United Kingdom, Portugal
Peng Liu

Not yet recruiting

The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train.

Histological or Cytological Confirmed Stage Ⅲ and Ⅳa Thymoma

China
Fudan University

Completed

Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer

Breast Cancer Female

China
Simcere Pharmaceutical Co., Ltd
The Affiliated Changzhou Tumor Hospital of Suzhou University

Unknown

FOLFOX4 Combined With Endostar in Patients With Advanced Colorectal Cancer

Colorectal Neoplasms

China
Shanghai Jiao Tong University School of Medicine

Recruiting

Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer (TCTN)

Breast Neoplasm

China
Martin-Luther-Universität Halle-Wittenberg
German Breast Group

Unknown

6xFU/Epirubicin/Cyclophosphamide (FEC) Compared to 3xFEC-3xDocetaxel in High-risk Node-negative Breast Cancer Patients (NNBC3-Europe)

Breast Cancer

Germany
Sun Yat-sen University

Recruiting

Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer

Breast Cancer

China
Shandong Cancer Hospital and Institute

Unknown

Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction (BCSMANC)

Breast Cancer

China
Tao OUYANG

Completed

Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer

Breast Cancer

China
Henan Cancer Hospital

Withdrawn

A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

Breast Cancer | HER2-positive Breast Cancer

China
Second Affiliated Hospital, School of Medicine,...
Women's Hospital School Of Medicine Zhejiang University; Zhejiang Provincial... and other collaborators

Recruiting

Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer

HER2-negative Breast Cancer | Neoadjuvant Chemotherapy

China
Fudan University

Active, not recruiting

TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature

Breast Cancer | Triple Negative Breast Cancer

China
Accelerated Community Oncology Research Network
Aventis Pharmaceuticals

Completed

Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients

Breast Neoplasm

United States
Jiangsu HengRui Medicine Co., Ltd.
Shanghai Pulmonary Hospital, Shanghai, China

Terminated

SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer

Non Squamous Non Small Cell Lung

China
Translational Research Center for Medical Innovation...

Completed

Epirubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab in Treating Women With HER2-Positive Stage III or Stage IV Breast Cancer

Breast Cancer

Japan
NCIC Clinical Trials Group

Completed

Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer

Breast Cancer

Canada
Medical University of South Carolina

Terminated

Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer

Prostate Cancer

United States
GERCOR - Multidisciplinary Oncology Cooperative...

Unknown

Docetaxel and Epirubicin as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Adenocarcinoma of the Stomach

Gastric Cancer

France
Fudan University
Chinese Anti-Cancer Association

Completed

Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN)

Triple Negative Breast Cancer
NCIC Clinical Trials Group

Completed

Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer

Breast Cancer | Neutropenia

Canada
University of Bergen
Haukeland University Hospital

Active, not recruiting

Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer (DDP)

Stage III Breast Cancer AJCC V7

Norway
Yonsei University

Completed

Docetaxel and Epirubicin in Advanced Gastric Cancer

Stomach Neoplasms

Korea, Republic of
Fudan University

Completed

Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations

Breast Cancer

China
Cancer Institute and Hospital, Chinese Academy...
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study

Breast Cancer

China
Heinrich-Heine University, Duesseldorf

Unknown

Combination Chemotherapy With or Without Darbepoetin Alfa in Treating Women With Stage III Breast Cancer

Breast Cancer

Germany
Peking University People's Hospital

Recruiting

Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients

HER2-negative Early Breast Cancer

China
Hospices Civils de Lyon

Completed

A Pilot Dose Escalation Trial of a Densified Chemotherapy Association of Docetaxel and Epirubicin Driven by Mathematical Modeling in Metastatic Breast Cancer Patients: The MODEL1 Study (MODEL1)

Metastatic Breast Cancer
Georgetown University

Recruiting

RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer (RAGE)

Non-metastatic Breast Cancer | Cancer Related Cognitive Decline

United States
Klinikum Weissenfels

Completed

Neoadjuvant Chemotherapy of Primary Breast Cancer With Epirubicin/Docetaxel and Carboplatin/Docetaxel (ETCat01)

Primary Breast Cancer

Germany
German Breast Group

Completed

Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer

Breast Cancer

Germany
Infinity Pharmaceuticals, Inc.

Completed

A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

United States, Hungary, Taiwan, Korea, Republic of, Russian Federation, Romania

3

Subscribe